113 related articles for article (PubMed ID: 34076977)
1. TUSC8 enhances cisplatin sensitivity of NSCLC cells through regulating VEGFA.
Shi N; Feng D; Gu Y; Zheng C; Miao M
J BUON; 2021; 26(2):336-344. PubMed ID: 34076977
[TBL] [Abstract][Full Text] [Related]
2. Effect of lncRNA-BLACAT1 on drug resistance of non-small cell lung cancer cells in DDP chemotherapy by regulating cyclin D1 expression.
Ju ZS; Sun B; Bao D; Zhang XF
Eur Rev Med Pharmacol Sci; 2020 Sep; 24(18):9465-9472. PubMed ID: 33015788
[TBL] [Abstract][Full Text] [Related]
3. LncRNA BC200 regulates the cell proliferation and cisplatin resistance in non-small cell lung cancer via PI3K/AKT pathway.
Gao BB; Wang SX
Eur Rev Med Pharmacol Sci; 2019 Feb; 23(3):1093-1101. PubMed ID: 30779077
[TBL] [Abstract][Full Text] [Related]
4. Upregulation of Long Noncoding RNA (lncRNA) X-Inactive Specific Transcript (XIST) is Associated with Cisplatin Resistance in Non-Small Cell Lung Cancer (NSCLC) by Downregulating MicroRNA-144-3p.
Tian LJ; Wu YP; Wang D; Zhou ZH; Xue SB; Zhang DY; Wei YG; Liu W
Med Sci Monit; 2019 Oct; 25():8095-8104. PubMed ID: 31659146
[TBL] [Abstract][Full Text] [Related]
5. LncRNA TATDN1 contributes to the cisplatin resistance of non-small cell lung cancer through TATDN1/miR-451/TRIM66 axis.
Wang L; Shang X; Feng Q
Cancer Biol Ther; 2019; 20(3):261-271. PubMed ID: 30481109
[TBL] [Abstract][Full Text] [Related]
6. LncRNA SNHG12 in extracellular vesicles derived from carcinoma-associated fibroblasts promotes cisplatin resistance in non-small cell lung cancer cells.
Tan D; Li G; Zhang P; Peng C; He B
Bioengineered; 2022 Jan; 13(1):1838-1857. PubMed ID: 35014944
[TBL] [Abstract][Full Text] [Related]
7. LncRNA TRERNA1 promotes malignant progression of NSCLC through targeting FOXL1.
Luo DB; Lv HB; Sun XH; Wang Y; Chu JH; Salai AL
Eur Rev Med Pharmacol Sci; 2020 Feb; 24(3):1233-1242. PubMed ID: 32096153
[TBL] [Abstract][Full Text] [Related]
8. LncRNA TUSC8 suppresses the proliferation and migration of esophageal cancer cells by downregulation of VEGFA.
Hu R; Bi R; Jiang L; Yang X; Zhong Y; Xie X
J Cancer; 2021; 12(21):6393-6400. PubMed ID: 34659529
[No Abstract] [Full Text] [Related]
9. LncRNA BX357664 inhibits the proliferation and invasion of non-small cell lung cancer cells.
Yang J; Du YM; Li B
Eur Rev Med Pharmacol Sci; 2019 Jan; 23(2):660-669. PubMed ID: 30720174
[TBL] [Abstract][Full Text] [Related]
10. Long non‑coding RNA LUCAT1 contributes to cisplatin resistance by regulating the miR‑514a‑3p/ULK1 axis in human non‑small cell lung cancer.
Shen Q; Xu Z; Xu S
Int J Oncol; 2020 Oct; 57(4):967-979. PubMed ID: 32945379
[TBL] [Abstract][Full Text] [Related]
11. LncRNA SNHG1 contributes to the cisplatin resistance and progression of NSCLC via miR-330-5p/DCLK1 axis.
Ge P; Cao L; Zheng M; Yao Y; Wang W; Chen X
Exp Mol Pathol; 2021 Jun; 120():104633. PubMed ID: 33753110
[TBL] [Abstract][Full Text] [Related]
12. LncRNA NNT-AS1 is a major mediator of cisplatin chemoresistance in non-small cell lung cancer through MAPK/Slug pathway.
Cai Y; Dong ZY; Wang JY
Eur Rev Med Pharmacol Sci; 2018 Aug; 22(15):4879-4887. PubMed ID: 30070323
[TBL] [Abstract][Full Text] [Related]
13. LncRNA PCAT1 Interacts with DKC1 to Regulate Proliferation, Invasion and Apoptosis in NSCLC Cells via the VEGF/AKT/Bcl2/Caspase9 Pathway.
Liu SY; Zhao ZY; Qiao Z; Li SM; Zhang WN
Cell Transplant; 2021; 30():963689720986071. PubMed ID: 33461333
[TBL] [Abstract][Full Text] [Related]
14. ELF1 activated long non-coding RNA CASC2 inhibits cisplatin resistance of non-small cell lung cancer via the miR-18a/IRF-2 signaling pathway.
Xiao XH; He SY
Eur Rev Med Pharmacol Sci; 2020 Mar; 24(6):3130-3142. PubMed ID: 32271431
[TBL] [Abstract][Full Text] [Related]
15. Effects of long non-coding RNA (lncRNA) cancer susceptibility candidate 2c (CASC2c) on proliferation, metastasis and drug resistance of non-small cell lung cancer (NSCLC) cells through ERK1/2 and β-catenin signaling pathways.
Tong L; Wu W
Pathol Res Pract; 2019 Sep; 215(9):152522. PubMed ID: 31300295
[TBL] [Abstract][Full Text] [Related]
16. LncRNA WT-AS inhibits metastatic ability of non-small cell lung cancer by regulating KLK13.
Wang Y; Tan TZ; Wang LQ; Zhang K
Eur Rev Med Pharmacol Sci; 2020 Sep; 24(18):9429-9437. PubMed ID: 33015785
[TBL] [Abstract][Full Text] [Related]
17. Deregulation of lncRNA-AC078883.3 and microRNA-19a is involved in the development of chemoresistance to cisplatin via modulating signaling pathway of PTEN/AKT.
Xing S; Qu Y; Li C; Huang A; Tong S; Wu C; Fan K
J Cell Physiol; 2019 Dec; 234(12):22657-22665. PubMed ID: 31111480
[TBL] [Abstract][Full Text] [Related]
18. c-Myc-activated long non-coding RNA H19 downregulates miR-107 and promotes cell cycle progression of non-small cell lung cancer.
Cui J; Mo J; Luo M; Yu Q; Zhou S; Li T; Zhang Y; Luo W
Int J Clin Exp Pathol; 2015; 8(10):12400-9. PubMed ID: 26722426
[TBL] [Abstract][Full Text] [Related]
19. Study on expression of lncRNA RGMB-AS1 and repulsive guidance molecule b in non-small cell lung cancer.
Li P; Li J; Yang R; Zhang F; Wang H; Chu H; Lu Y; Dun S; Wang Y; Zang W; Du Y; Chen X; Zhao G; Zhang G
Diagn Pathol; 2015 Jun; 10():63. PubMed ID: 26055877
[TBL] [Abstract][Full Text] [Related]
20. Targeting MALAT1 induces DNA damage and sensitize non-small cell lung cancer cells to cisplatin by repressing BRCA1.
Huang J; Lin C; Dong H; Piao Z; Jin C; Han H; Jin D
Cancer Chemother Pharmacol; 2020 Nov; 86(5):663-672. PubMed ID: 33030583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
